Outcome and prognostic factors of children with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib followed by allogeneic hematopoietic cell transplantation in first remission.
Conclusion: Decrement in RQ-PCR for the BCR-ABL1 transcript that was determined after consolidation was the only significant prognostic factor for incidence of molecular relapse. In the post-induction TKI initiation setting, steadfast imatinib treatment during consolidation may allow for optimum post-HCT outcomes.
PMID: 30956963 [PubMed]
Source: Blood Research - Category: Hematology Tags: Blood Res Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Chemotherapy | Children | Gleevec | Hematology | Leukemia | Study | Transplants